Adjuvant therapy for colon cancer: Present and perspectives

被引：35

作者：

De Dosso, S.

Sessa, C. ^{[1
]}

Saletti, P. ^{[1
]}

机构：

[1] Oncol Inst So Switzerland, Res Unit, CH-6500 Bellinzona, Switzerland

来源：

CANCER TREATMENT REVIEWS | 2009年 / 35卷 / 02期

关键词：

Colon cancer; Adjuvant chemotherapy; Targeted therapy; TUMOR MICROSATELLITE-INSTABILITY; 18Q ALLELIC LOSS; COLORECTAL-CANCER; STAGE-II; POOLED ANALYSIS; PHASE-III; BOLUS FLUOROURACIL/LEUCOVORIN; RANDOMIZED-TRIAL; ORAL LEUCOVORIN; END-POINTS;

D O I：

10.1016/j.ctrv.2008.10.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Colon cancer is the second cause of death for cancer worldwide. In most cases it is diagnosed when it is still localized to the intestinal wall or in regional lymphnodes. Post-operative systemic therapy with 5-fluorouracil and folinic acid in combination with Oxaliplatin is the standard option for patients with radically resected stage III disease. In stage II, the value of a post-operative treatment remains controversial, but the identification of prognostic factors, histopathological and molecular, may allow the selection of patients who can benefit from adjuvant treatment. The inclusion of molecular targeted agents in combination regimens with cytotoxics, already proven effective in advanced disease, is the main field of development in the most recent protocols of adjuvant therapy. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：160 / 166

页数：7

共 63 条

[1]

Ahnen DJ, 1998, CANCER RES, V58, P1149

[2]

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[3]

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer:: Results of a randomized trial [J].

André, T ;

Colin, P ;

Louvet, C ;

Gamelin, E ;

Bouche, O ;

Achille, E ;

Colbert, N ;

Boaziz, C ;

Piedbois, P ;

Tubiana-Mathieu, N ;

Boutan-Laroze, A ;

Flesch, M ;

Buyse, M ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2896-2903

[4]

[Anonymous], P AM SOC CLIN ONCO S

[5]

BOKEMEYER C, 2008, J CLIN ONCOL S, V26, P20

[6]

BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571

[7]

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer [J].

Carmichael, J ;

Popiela, T ;

Radstone, D ;

Falk, S ;

Borner, M ;

Oza, A ;

Skovsgaard, T ;

Munier, S ;

Martin, C .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3617-3627

[8]

First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin [J].

Cassidy, J ;

Twelves, C ;

Van Cutsem, E ;

Hoff, P ;

Bajetta, E ;

Boyer, M ;

Bugat, R ;

Burger, U ;

Garin, A ;

Graeven, U ;

McKendrick, J ;

Maroun, J ;

Marshall, J ;

Osterwalder, B ;

Pérez-Manga, G ;

Rosso, R ;

Rougier, P ;

Schilsky, RL .

ANNALS OF ONCOLOGY, 2002, 13 (04) :566-575

[9]

CASSIDY J, 2006, J CLIN ONCOL, V24, pS18

[10]

Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer [J].

Cassidy, Jim ;

Schmoll, Hans-Joachim ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :226-227

← 1 2 3 4 5 6 7 →